Tag Archives: Eli Lilly and Company

J.P. Morgan Turns All Eyes toward Biotech

CEO2013_115x75_Thumbnail copy

BioWorld’s Peter Winter reports that the mood is upbeat at today’s kickoff of the 33rd annual J.P. Morgan Healthcare Conference in San Francisco (check out the story here, subscription required). Winter points to coming off ‘a record year in terms of raising capital, performance on the capital markets and partnering and mergers and acquisitions’ as one reason for the strong momentum at this year’s conference. Looking ahead, Roth Capital Partners’ John Chambers shared with Winter Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

2011 BIO International Convention Super Sessions

2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,